Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BridgeBio Pharma Inc.

    NASDAQ: BBIO · Real-Time Price · USD
    41.04
    1.26 (3.17%)
    At close: Jun 16, 2025, 3:59 PM
    41.15
    0.27%
    After-hours: Jun 16, 2025, 07:59 PM EDT

    BridgeBio Pharma Statistics

    Share Statistics

    BridgeBio Pharma has 189.88M shares outstanding. The number of shares has increased by 1.64% in one year.

    Shares Outstanding

    n/a
    		 189.88M

    Shares Change (YoY)

    n/a
    		 1.64%

    Shares Change (QoQ)

    n/a
    		 0.63%

    Owned by Institutions (%)

    n/a
    		 93.73%

    Shares Floating

    n/a
    		 160.74M

    Failed to Deliver (FTD) Shares

    n/a
    		 25,781

    FTD / Avg. Volume

    n/a
    		 0.9%

    Short Selling Information

    The latest short interest is 21.99M, so 11.58% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 21.99M

    Short % of Shares Out

    n/a
    		 11.58%

    Short % of Float

    n/a
    		 19.52%

    Short Ratio (days to cover)

    n/a
    		 10.13

    Valuation Ratios

    The PE ratio is -9.53 and the forward PE ratio is -22.2. BridgeBio Pharma's PEG ratio is 0.35.

    PE Ratio

    n/a
    		 -9.53

    Forward PE

    n/a
    		 -22.2

    PS Ratio

    n/a
    		 23.01

    Forward PS

    n/a
    		 3

    PB Ratio

    n/a
    		 -3.5

    P/FCF Ratio

    n/a
    		 -9.79

    PEG Ratio

    n/a
    		 0.35
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for BridgeBio Pharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.67, with a Debt / Equity ratio of -1.19.

    Current Ratio

    n/a
    		 4.67

    Quick Ratio

    n/a
    		 4.67

    Debt / Equity

    n/a
    		 -1.19

    Debt / EBITDA

    n/a
    		 -3.96

    Debt / FCF

    n/a
    		 -3.32

    Interest Coverage

    n/a
    		 -5.97

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $306,071.72

    Profits Per Employee

    n/a
    		 $-738,982.07

    Employee Count

    n/a
    		 725

    Asset Turnover

    n/a
    		 0.24

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 1.15M

    Effective Tax Rate

    n/a
    		 -0.21%

    Stock Price Statistics

    The stock price has increased by 50.72% in the last 52 weeks. The beta is 1.1, so BridgeBio Pharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.1

    52-Week Price Change

    n/a
    		 50.72%

    50-Day Moving Average

    n/a
    		 35.35

    200-Day Moving Average

    n/a
    		 30.84

    Relative Strength Index (RSI)

    n/a
    		 71.81

    Average Volume (20 Days)

    n/a
    		 2,870,033

    Income Statement

    In the last 12 months, BridgeBio Pharma had revenue of 221.9M and earned -535.76M in profits. Earnings per share was -2.88.

    Revenue

    n/a
    		 221.9M

    Gross Profit

    n/a
    		 218.02M

    Operating Income

    n/a
    		 -592.97M

    Net Income

    n/a
    		 -535.76M

    EBITDA

    n/a
    		 -436.83M

    EBIT

    n/a
    		 -442.9M

    Earnings Per Share (EPS)

    n/a
    		 -2.88
    Full Income Statement

    Balance Sheet

    The company has 681.1M in cash and 1.73B in debt, giving a net cash position of -1.05B.

    Cash & Cash Equivalents

    n/a
    		 681.1M

    Total Debt

    n/a
    		 1.73B

    Net Cash

    n/a
    		 -1.05B

    Retained Earnings

    n/a
    		 -3.1B

    Total Assets

    n/a
    		 881.64M

    Working Capital

    n/a
    		 543.07M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -520.73M and capital expenditures -933K, giving a free cash flow of -521.66M.

    Operating Cash Flow

    n/a
    		 -520.73M

    Capital Expenditures

    n/a
    		 -933K

    Free Cash Flow

    n/a
    		 -521.66M

    FCF Per Share

    n/a
    		 -2.8
    Full Cash Flow Statement

    Margins

    Gross margin is 98.25%, with operating and profit margins of -267.22% and -241.44%.

    Gross Margin

    n/a
    		 98.25%

    Operating Margin

    n/a
    		 -267.22%

    Pretax Margin

    n/a
    		 -244.34%

    Profit Margin

    n/a
    		 -241.44%

    EBITDA Margin

    n/a
    		 -196.86%

    EBIT Margin

    n/a
    		 -267.22%

    FCF Margin

    n/a
    		 -235.09%

    Dividends & Yields

    BBIO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BBIO is $50, which is 21.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $50

    Price Target Difference

    n/a
    		 21.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 12
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.91

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist